Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | PRNP | P04156 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3494396 | 0.92 | POLB (0.40) | LMNAPOLBTP53 | |
| SCHEMBL4965332 | 0.83 | CACNB4 (0.46) | MEN1KMT2ALMNAALDH1A1POLB | |
| SCHEMBL3496055 | 0.82 | GRIN2B (0.42) | MEN1KMT2ALMNAALDH1A1GRIN2B | |
| SCHEMBL3495640 | 0.80 | IDO1 (0.38) | MEN1KMT2ALMNAALDH1A1POLB | |
| SCHEMBL4964868 | 0.80 | CYP19A1 (0.39) | MEN1KMT2ALMNAALDH1A1POLB | |
| SCHEMBL3495130 | 0.78 | KMT2A (0.43) | MEN1KMT2ALMNAALDH1A1GRIN2B | |
| SCHEMBL3497512 | 0.78 | TP53 (0.45) | MEN1KMT2AALDH1A1POLBTP53 | |
| SCHEMBL3494652 | 0.78 | CACNB4 (0.40) | MEN1KMT2AALDH1A1POLB | |
| SCHEMBL3496066 | 0.78 | CACNB4 (0.40) | ALDH1A1 | |
| SCHEMBL14302885 | 0.77 | ALDH1A1 (0.37) | MEN1KMT2AALDH1A1POLBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137283-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2010-06-03 | — | — | US | claimed |
| EP-1751157-B1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER (US) | 2007-10-03 | — | — | EP | claimed |
| EP-1751157-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC. (US) | 2007-02-14 | — | — | EP | claimed |
| US-20050277661-A1 | Inhibitors of the HIV integrase enzyme | AGOURON PHARMACEUTICALS, INC. | 2005-12-15 | — | — | US | claimed |
| WO-2005103051-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC. (US) | 2005-11-03 | — | — | WO | claimed |
| US-20100137283-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2010-06-03 | — | — | US | disclosed |
| US-20100137283-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2010-06-03 | — | — | US | disclosed |
| US-20100137283-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2010-06-03 | — | — | US | disclosed |
| US-7692014-B2 | Inhibitors of the HIV integrase enzyme | PFIZER, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7692014-B2 | Inhibitors of the HIV integrase enzyme | PFIZER, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7692014-B2 | Inhibitors of the HIV integrase enzyme | PFIZER, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| EP-1873155-A1 | Inhibitors of the HIV integrase enzyme | PFIZER INC. (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1873155-A1 | Inhibitors of the HIV integrase enzyme | PFIZER INC. (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1751157-B1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER (US) | 2007-10-03 | — | — | EP | disclosed |
| EP-1751157-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC. (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20050277661-A1 | Inhibitors of the HIV integrase enzyme | AGOURON PHARMACEUTICALS, INC. | 2005-12-15 | — | — | US | disclosed |
| WO-2005103051-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC. (US) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277661-A1 | Inhibitors of the HIV integrase enzyme | IMPDH1, INTS9, TYMP | MEN1 4787/4885KMT2A 1367/4885LMNA 3259/4885 |
| US-20100137283-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | IMPDH1, INTS9, TYMP | MEN1 4787/4885KMT2A 1367/4885LMNA 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.